MSB 8.14% $1.20 mesoblast limited

Ann: FDA Grants Orphan Drug Designation for Revascor, page-52

  1. 168 Posts.
    lightbulb Created with Sketch. 90
    The response in US would be much better, as investors over there understand the value of Orphan drug status for rare diseases. Just keep on holding fellows, Hopefully they will be spike tomorrow. Australians investors biased towards mining.

    One more news about presentation about the revenue and countries they can use this drug for the treatment would be awesome. , I have reached my limit of buying. It will be silly to sell now as we are not far from FDA approval
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.20
Change
0.090(8.14%)
Mkt cap ! $1.358B
Open High Low Value Volume
$1.10 $1.20 $1.09 $9.935M 8.613M

Buyers (Bids)

No. Vol. Price($)
28 96840 $1.19
 

Sellers (Offers)

Price($) Vol. No.
$1.20 83806 11
View Market Depth
Last trade - 14.20pm 12/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.